|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM370594312 |
| 003 |
DE-627 |
| 005 |
20250306010128.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240404s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2024.110196
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1234.xml
|
| 035 |
|
|
|a (DE-627)NLM370594312
|
| 035 |
|
|
|a (NLM)38570004
|
| 035 |
|
|
|a (PII)S1521-6616(24)00087-1
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kinoshita, Riku
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Methylation levels of the IL10 gene in peripheral blood are related to the intractability of Graves' disease
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.05.2024
|
| 500 |
|
|
|a Date Revised 21.08.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023. Published by Elsevier Inc.
|
| 520 |
|
|
|a The prognosis of autoimmune thyroid diseases (AITDs), including Hashimoto's disease (HD) and Graves' disease (GD), is difficult to predict. DNA methylation regulates gene expression of immune mediating factors. Interleukin (IL)-10 is a Th2 cytokine that downregulates inflammatory cytokines produced by Th1 cells. To clarify the role of methylation of the IL10 gene in the prognosis of AITD, we evaluated the methylation levels of two CpG sites in the IL10 promoter using pyrosequencing. The methylation levels of the -185 CpG site of the IL10 gene were related to age and GD intractability in GD patients. Furthermore, the C carrier of the IL10-592 A/C polymorphism was related to low methylation levels of the -185 CpG site. The methylation levels of the IL10-185 CpG site of the IL10 gene were related to the intractability of GD and were lower in individuals with the C allele of the IL10-592 A/C polymorphism
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Autoimmune thyroid disease
|
| 650 |
|
4 |
|a IL-10
|
| 650 |
|
4 |
|a Intractability
|
| 650 |
|
4 |
|a Methylation
|
| 650 |
|
4 |
|a Polymorphism
|
| 650 |
|
4 |
|a Pyrosequencing
|
| 650 |
|
4 |
|a Severity
|
| 650 |
|
7 |
|a IL10 protein, human
|2 NLM
|
| 700 |
1 |
|
|a Inoue, Naoya
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Iwatani, Yoshinori
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Noguchi, Yusuke
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hidaka, Yoh
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Watanabe, Mikio
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 263(2024) vom: 15. Juni, Seite 110196
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:263
|g year:2024
|g day:15
|g month:06
|g pages:110196
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2024.110196
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 263
|j 2024
|b 15
|c 06
|h 110196
|